BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:bexobrutideg readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of bexobrutideg\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05131022-10973@assetmemo.bio
DTSTAMP:20261121T005447Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:bexobrutideg: Phase 1 readout est. (NCT05131022)
DESCRIPTION:bexobrutideg\, phase 1\, Chronic Lymphocytic Leukemia.\nStudy: 
 A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies\
 nEstimated primary completion: January 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/bexobrutideg#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT05131022
URL:https://assetmemo.bio/drug/bexobrutideg#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221500-10973@assetmemo.bio
DTSTAMP:20261121T005447Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:bexobrutideg: Phase 2 readout est. (NCT07221500)
DESCRIPTION:bexobrutideg\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: 
 A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton
 's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak C
 LL-201)\nEstimated primary completion: January 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/bexobrutideg#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07221500
URL:https://assetmemo.bio/drug/bexobrutideg#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07516093-10973@assetmemo.bio
DTSTAMP:20261121T005447Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:bexobrutideg: Phase 3 readout est. (NCT07516093)
DESCRIPTION:bexobrutideg\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: 
 Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL\nEstimated primary co
 mpletion: October 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/bexobrutideg#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07516093
URL:https://assetmemo.bio/drug/bexobrutideg#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07520006-10973@assetmemo.bio
DTSTAMP:20261121T005447Z
DTSTART;VALUE=DATE:20330531
DTEND;VALUE=DATE:20330601
SUMMARY:bexobrutideg: Phase 1/2 readout est. (NCT07520006)
DESCRIPTION:bexobrutideg\, phase 1/2\, Chronic Lymphocytic Leukemia.\nStudy
 : Study of NX-5948 in Combination With Other Agents in Adults With B-cell 
 Malignancies\nEstimated primary completion: May 2033. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/bexobrutideg#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07520006
URL:https://assetmemo.bio/drug/bexobrutideg#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
